drugset / Trial / NCT01756508
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
RandomizedParallel-groupOpen-labelPrevention
Summary
Study of eculizumab ability to correct the reperfusion injury of the kidney allograft.
Timeline
- Start
- 2012-09-01
- Primary completion
- 2017-04-15
- Completion
- 2017-12-01
Publications
- Background de Vries DK, van der Pol P, van Anken GE, van Gijlswijk DJ, Damman J, Lindeman JH, Reinders ME, Schaapherder AF, Kooten Cv. Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation. Transplantation. 2013 Mar 27;95(6):816-20. doi: 10.1097/TP.0b013e31827e31c9.
- Background Kaabak M, Babenko N, Shapiro R, Zokoyev A, Dymova O, Kim E. A prospective randomized, controlled trial of eculizumab to prevent ischemia-reperfusion injury in pediatric kidney transplantation. Pediatr Transplant. 2018 Mar;22(2). doi: 10.1111/petr.13129. Epub 2018 Jan 29.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eculizumab | Monoclonal antibody | 1200 mg/m2 | — |